<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250311065040N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-04-22</date_registration>
      <primary_sponsor>Birjand University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of  the effect of an artificial saliva produced from aqueous extract of Okra ( Abelmoschus Esculentus) on  the xerostomia symptoms in diabetic patients</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of  the effect of an artificial saliva produced from aqueous extract of Okra ( Abelmoschus Esculentus) on  the xerostomia symptoms in diabetic patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-05-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/82437</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are divided into two groups 1 (intervention) and 2 (control) using a block randomization method, for this purpose, blocks of four are formed including A, B. (For example: AABB, BABA, ABAB) Then, until the sample is completed, the blocks are selected by simple random selection. Also, A will be the intervention group (artificial saliva containing aqueous extract of okra) and B will be the control group (artificial saliva containing carboxymethyl cellulose), Blinding description: Study participants and the principal investigator (student performing the intervention and collecting the data) will be blinded by packaging the artificial saliva in the same way and not being aware of the assignment of individuals to the study groups.</study_design>
      <phase>3</phase>
      <hc_freetext>Xerostomia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: People in this group, including 40 patients, will rinse their mouths with 2 ml of aqueous extract of okra fruit (30 g sorbitol, 11.7 g aqueous extract of okra, 804 mg dipotassium mono hydrogen phosphate, 625 mg potassium chloride, 366 mg potassium dihydrogen phosphate, 166 mg calcium chloride, 59 mg magnesium chloride, and sodium benzoate at a rate of 0.05% of the total solution as a preservative in 1000 g distilled water) 3 times a day for 2 weeks. Intervention 2: Control group: People in this group, including 40 patients, will rinse their mouths with 2 ml of carboxymethylcellulose solution with the formula (30 g sorbitol, 11.7 g carboxymethylcellulose, 804 mg dipotassium mono hydrogen phosphate, 625 mg potassium chloride, 366 mg potassium dihydrogen phosphate, 166 mg calcium chloride, 59 mg magnesium chloride and sodium benzoate at a rate of 0.05% of the total solution as a preservative in 1000 g distilled water) 3 times a day for 2 weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hossein Shirmehenji</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Birjand Dental School, Corner of Pasdaran 3, Pasdaran Blvd.</address>
        <city>Birjand</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1713643135</zip>
        <telephone>+98 56 3238 1700</telephone>
        <email>h.shirmehenji@bums.ac.ir</email>
        <affiliation>Birjand University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Parvin Parvaie</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Birjand Dental School, Corner of Pasdaran 3, Pasdaran Blvd.</address>
        <city>Birjand</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1713643135</zip>
        <telephone>+98 56 3238 1700</telephone>
        <email>parvin.parvaie@yahoo.com</email>
        <affiliation>Birjand University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Be between the ages of 18 and 65 years old
Patients must have dry mouth, based on the Fox questionnaire with at least a positive response to 4 of the 9 questions on the questionnaire
Diabetes based on diabetes diagnosis criteria</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnancy
Taking medications that reduce salivation
Use of other artificial saliva products
History of autoimmune diseases
History of pneumonia
Presence of oral or perioral lesions</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K11.7</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Disturbances of salivary secretion</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: People in this group, including 40 patients, will rinse their mouths with 2 ml of aqueous extract of okra fruit (30 g sorbitol, 11.7 g aqueous extract of okra, 804 mg dipotassium mono hydrogen phosphate, 625 mg potassium chloride, 366 mg potassium dihydrogen phosphate, 166 mg calcium chloride, 59 mg magnesium chloride, and sodium benzoate at a rate of 0.05% of the total solution as a preservative in 1000 g distilled water) 3 times a day for 2 weeks.</i_keyword>
      <i_keyword>Control group: People in this group, including 40 patients, will rinse their mouths with 2 ml of carboxymethylcellulose solution with the formula (30 g sorbitol, 11.7 g carboxymethylcellulose, 804 mg dipotassium mono hydrogen phosphate, 625 mg potassium chloride, 366 mg potassium dihydrogen phosphate, 166 mg calcium chloride, 59 mg magnesium chloride and sodium benzoate at a rate of 0.05% of the total solution as a preservative in 1000 g distilled water) 3 times a day for 2 weeks.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Score obtained on the Fox questionnaire. Timepoint: Days 0 and 14 of the study. Method of measurement: Fox Dry Mouth Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Birjand University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-03-15</approval_date>
        <contact_name>Ethics Committee of Birjand University of Medical Sciences</contact_name>
        <contact_address>Ghafari Birjand South Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
